JonesResearch notes Trevi Therapeutics (TRVI) shared positive update from the planned sample size re-estimation in ongoing Phase 2b CORAL trial in IPF-cough. In line with the firm’s bull case expectations, SSRE analysis suggested that CORAL trial should continue as planned, with no upsizing needed, keeping topline data on track for the first half of 2025. A favorable SSRE analysis, increases JonesResearch’s confidence that the statistical assumptions in CORAL are adequate. The drug is highly likely to show a clinically meaningful and statistically significant cough reduction in CORAL, the firm adds, reiterating a Buy rating on the shares.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRVI:
- H.C. Wainwright ups Trevi Therapeutics target after ‘best-case’ for CORAL
- Trevi Therapeutics provides update on Phase 2b trial of Haduvio in IPF
- Trevi Therapeutics price target raised to $9 from $8 at JonesResearch
- Trevi Therapeutics selloff on data unwarranted, says H.C. Wainwright
- Trevi Therapeutics announces results from HAP study of oral nalbuphine